Apraglutide
Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Key Facts
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a mission-driven, publicly traded biotech dedicated to advancing the treatment of gastrointestinal diseases and redefining the standard of care. Its cornerstone achievement is the discovery, development, and commercialization of the first-in-class GC-C agonist LINZESS® (linaclotide), a blockbuster therapy for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's strategy centers on leveraging its proprietary GI platforms, commercial infrastructure, and deep scientific expertise to build a pipeline targeting organic GI diseases with high unmet need, including the late-stage development of apraglutide for short bowel syndrome.
View full company profileAbout Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a mission-driven, publicly traded biotech dedicated to advancing the treatment of gastrointestinal diseases and redefining the standard of care. Its cornerstone achievement is the discovery, development, and commercialization of the first-in-class GC-C agonist LINZESS® (linaclotide), a blockbuster therapy for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's strategy centers on leveraging its proprietary GI platforms, commercial infrastructure, and deep scientific expertise to build a pipeline targeting organic GI diseases with high unmet need, including the late-stage development of apraglutide for short bowel syndrome.
View full company profileTherapeutic Areas
Other Short Bowel Syndrome with Intestinal Failure (SBS-IF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Crofelemer | Jaguar Health | Proof-of-Concept |